Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
07:00am, Tuesday, 01'st Apr 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTO
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
08:01pm, Monday, 03'rd Mar 2025
Fractyl Health, Inc. (NASDAQ:GUTS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Brian Luque – Head of Investor Relations and Corporate Development Harith Rajagopal
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
04:05pm, Monday, 03'rd Mar 2025
Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full stu
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
07:00am, Monday, 24'th Feb 2025
BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the
After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS)
10:36am, Wednesday, 12'th Feb 2025
Fractyl Health, Inc. (GUTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning
Prioritizing Revita's clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint da
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose Results confirm ability to directly target pancreas with novel delivery catheter and route of administrat
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Fractyl Health to Participate in the Upcoming December Conferences
07:00am, Tuesday, 26'th Nov 2024
BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
11:01pm, Thursday, 14'th Nov 2024
Fractyl Health, Inc. (NASDAQ:GUTS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-Founder and CEO Lisa Dav
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:05pm, Tuesday, 12'th Nov 2024
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024 Top
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
07:00am, Tuesday, 29'th Oct 2024
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
07:00am, Monday, 28'th Oct 2024
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
